| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | — | +1165.0% |
| Cost of Revenue | $4.9M | — | +131.8% |
| Gross Profit | -$3.4M | — | -68.1% |
| R&D Expense | $566K | — | -2.9% |
| SG&A Expense | $3.2M | — | +76.5% |
| Operating Income | -$7.6M | — | +28.9% |
| Net Income | -$7.6M | — | +26.2% |
| EPS (Basic) | $0.00 | — | — |
| EPS (Diluted) | $0.00 | — | — |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $22.3M | -23.3% | +95.4% |
| Accounts Receivable | $1.1M | +2648.8% | +2789.7% |
| Inventory | $18.2M | -3.6% | -23.6% |
| Current Assets | $42.8M | -12.4% | -10.6% |
| Total Assets | $61.7M | -11.0% | -14.8% |
| Current Liabilities | $12.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$7.1M | — | +43.1% |
| Capital Expenditures | $100K | — | +0.0% |
| Investing Cash Flow | -$191K | — | -102.2% |
| Financing Cash Flow | $542K | — | -94.3% |
| Free Cash Flow | -$7.2M | — | +42.8% |
| -5.4% |
| Total Liabilities | $14.9M | -2.1% | -21.1% |
| Stockholders' Equity | $46.7M | -13.5% | -12.7% |